Clinical Trial Update: OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating erlotinib (OSI-774) in combination with bevacizumab for metastatic renal cell carcinoma has completed. The update summarizes the Phase …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Avastin (bevacizumab)
• Tarceva (erlotinib)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Kidney Cancer | Phase 2 | Status: COMPLETED